ARTEMIS stabilizes the genome and modulates proliferative responses in multipotent mesenchymal cells
- Sarah A Maas†1, 2,
- Nina M Donghia†1,
- Kathleen Tompkins1, 3,
- Oded Foreman4 and
- Kevin D Mills1, 5Email author
© Maas et al; licensee BioMed Central Ltd. 2010
Received: 18 August 2010
Accepted: 27 October 2010
Published: 27 October 2010
Unrepaired DNA double-stranded breaks (DSBs) cause chromosomal rearrangements, loss of genetic information, neoplastic transformation or cell death. The nonhomologous end joining (NHEJ) pathway, catalyzing sequence-independent direct rejoining of DSBs, is a crucial mechanism for repairing both stochastically occurring and developmentally programmed DSBs. In lymphocytes, NHEJ is critical for both development and genome stability. NHEJ defects lead to severe combined immunodeficiency (SCID) and lymphoid cancer predisposition in both mice and humans. While NHEJ has been thoroughly investigated in lymphocytes, the importance of NHEJ in other cell types, especially with regard to tumor suppression, is less well documented. We previously reported evidence that the NHEJ pathway functions to suppress a range of nonlymphoid tumor types, including various classes of sarcomas, by unknown mechanisms.
Here we investigate roles for the NHEJ factor ARTEMIS in multipotent mesenchymal stem/progenitor cells (MSCs), as putative sarcomagenic cells of origin. We demonstrate a key role for ARTEMIS in sarcoma suppression in a sensitized mouse tumor model. In this context, we found that ARTEMIS deficiency led to chromosomal damage but, paradoxically, enhanced resistance and proliferative potential in primary MSCs subjected to various stresses. Gene expression analysis revealed abnormally regulated stress response, cell proliferation, and signal transduction pathways in ARTEMIS-defective MSCs. Finally, we identified candidate regulatory genes that may, in part, mediate a stress-resistant, hyperproliferative phenotype in preneoplastic ARTEMIS-deficient MSCs.
Our discoveries suggest that Art prevents genome damage and restrains proliferation in MSCs exposed to various stress stimuli. We propose that deficiency leads to a preneoplastic state in primary MSCs and is associated with aberrant proliferative control and cellular stress resistance. Thus, our data reveal surprising new roles for ARTEMIS and the NHEJ pathway in normal MSC function and fitness relevant to tumor suppression in mesenchymal tissues.
Nonhomologous end joining (NHEJ) is a critical DNA double-stranded break repair pathway, important in the repair of general DNA double-stranded breaks and programmed DSBs generated during B- and T-lymphocyte development [1, 2]. Cells lacking NHEJ exhibit variable proliferative defects, hypersensitivity to ionizing radiation and other clastogens and spontaneous chromosomal instability. Numerous studies have implicated NHEJ as a key suppressor of lymphoid tumorigenesis, both in humans and in experimental models [3–5]. The tumor-suppressive role of NHEJ is thought to be largely via prevention of oncogenic chromosomal rearrangements relating to failed lymphocyte development. More recently, we and others have shown that NHEJ is a tumor-suppressive pathway in multiple nonlymphoid tissues, though the detailed mechanisms remain essentially unknown [6–8].
ARTEMIS (encoded by the Art/Dclre1c gene) is a DNA processing exo/endonuclease that acts together with the DNA-dependent protein kinase (DNA-PK) to prepare DNA ends for ligation by the core NHEJ machinery [9, 10]. Accumulating evidence has also pointed to DNA damage response or checkpoint activation roles for Art that may be distinct from its DNA repair activities [11–15]. Thus, Art may uniquely function as a key integrator of DNA damage signals, cellular response and DNA repair. In this context, Art is important in both general DNA double-stranded break (DSB) repair and in specialized repair of programmed DNA breaks during V(D)J recombination in developing B- and T-lymphocytes [3, 9, 10]. Mutations in Art underlie human radiosensitive severe combined immunodeficiency (RS-SCID) and SCID-A, primary immunodeficiencies associated with hypersensitivity to DNA-damaging agents and variable lymphoma predisposition [5, 9, 10, 16–18].
We recently demonstrated a role for Art in suppression of several classes of sarcomas, including osteosarcomas, chondrosarcomas, rhabdomyosarcomas and poorly differentiated anaplastic sarcomas. In this context, we postulate a role for Art in suppressing neoplastic transformation of mesenchymal stem/progenitor cells (MSCs), closely related multipotent mesenchymal stromal cells (MMS), or their descendants. MSCs and MMSs are multipotent cells that can give rise to multiple lineages, including bone, cartilage, fat and muscle [19–23]. MSCs may also be capable of hepatic, renal, cardiac or neural differentiation, at least in some limited contexts. In the bone marrow, MSCs and MMSs function as a stem/progenitor cell reservoir for renewal/replacement of numerous skeletal or associated cell types and function as stromal cells supporting hematopoietic stem cell differentiation/development [20, 23–25]. Owing to their capacity to differentiate along many different axes, MSCs are an extremely attractive candidate for use in regenerative medicine applications [20, 24]. In this context, it is critical to understand the mechanisms that govern both normal MSC fitness and activity and potential pathologies, especially cancers that may be linked with MSC derangement. However, the factors that influence the normal tissue-regenerative functions, while preventing neoplastic transformation, of MSCs remain poorly understood.
Our previous data suggested that patients with mutations in Art or other NHEJ factors may also be at risk for a host of nonlymphoid cancers, especially sarcomas, even if the immunodeficiency can be corrected by bone marrow transplantation or gene therapy . Here we have further investigated the mechanistic role of ARTEMIS in mesenchymal tumor suppression and in normal MSC function and fitness. The importance of ARTEMIS in primary MSC derived from the bone marrow microenvironment was tested in detail using knockout mice . We find that ARTEMIS is important for normal proliferative control of MSCs, especially after exposure to various cytostress stimuli. These findings add to the growing evidence that, in addition to DNA repair functions, ARTEMIS is a key factor in normal cell cycle response to cellular stressors, such as DNA damage [11–14]. In this context, we propose that Art-deficient MSCs acquire a preneoplastic state in which normal proliferative control is altered. The relevance to sarcomagenesis is discussed.
Results and Discussion
The NHEJ factor ARTEMIS suppresses sarcomagenesis
Although we could only obtain metaphase chromosome spreads from two Art-deficient sarcomas, spectral karyotype analysis of this sarcoma subset revealed aneuploidy and hyperdiploidy, without grossly detectable chromosomal translocations (Figure 1c; Additional file 1). While we cannot rule out chromosomal instability in some Art-deficient sarcomas, the spectral karyotypes we did analyze were reminiscent of human sarcoma karyotypes, which commonly show aneuploidization without consistent or clonal translocations [31–41]. These data suggest that Art may suppress sarcomagenesis by mechanisms that are at least partly independent of chromosomal stability control. In this context, the observed aneuploidization may be indicative of a defect in normal proliferation or growth control in the pretransformed or early transformed sarcoma cells of origin.
Artis required for genome stability in primary MSCs
The occurrence of poorly differentiated sarcomas in ArtΔ/Δ Trp53Δ/+ mice, as well as the range of differentiated cell types identified, suggested origination of these diverse tumors from a common precursor cell type. We therefore focused on the role of ARTEMIS in multipotent primary MSCs as candidate sarcoma cells of origin. We first evaluated whether Art is expressed in normal MSCs by a reverse transcriptase polymerase chain reaction (RT-PCR) assay, originally used to analyze Art-knockout (ArtΔ/Δ) embryonic stem cells . Total RNA was isolated from either wild-type (WT) or ArtΔ/Δ MSCs, isolated by standard methods from corresponding mice, and Art transcript was measured by RT-PCR [19, 42, 43]. This verified that Art is transcriptionally expressed in WT MSCs and confirmed ablation of Art in mutant MSCs (Additional file 2).
Artis dispensable for MSC differentiation
In addition to general differentiation competency, MSCs were assessed for proliferative responses during differentiation. WT or ArtΔ/Δ MSCs were transferred from standard growth to either adipogenic, osteogenic or control medium, cultured for up to 14 days and measured at various culture time points for mitotic index as a marker of actively proliferating cells by immunostaining for phosphorylated histone H3 (phospho-H3), a mitosis-specific marker.
During culture in nondifferentiation, adipogenic or osteogenic medium ArtΔ/Δ and WT MSC cultures exhibited similar phospho-H3 cell counts throughout the 14-day measurement time course (Figures 3d-g). Together with the differentiation data above, these results demonstrate that Art deficiency does not quantitatively affect the number of bone marrow MSCs, as defined by functional differentiation and cell proliferation assays.
Artmodulates the response to induced DNA damage in MSCs
Next, we evaluated ArtΔ/Δ versus WT MSCs for radiosensitivity by two different assays. First, we performed a colony formation assay following irradiation of WT or ArtΔ/Δ MSCs at doses ranging from 0 to 3.5 Gy. After irradiation, serial dilutions were plated and cultured until colonies were visibly evident in unirradiated samples. Colony counts were determined after staining with crystal violet, and all data were normalized to unirradiated colony counts. As controls, radiosensitivity was also determined for ArtΔ/Δ or WT fibroblasts, with the former previously shown to be hypersensitive to IR exposure . ArtΔ/Δ fibroblasts expectedly showed IR hypersensitivity relative to WT fibroblasts, especially at intermediate doses (Figure 4c). By contrast, ArtΔ/Δ and WT MSCs were essentially indistinguishable for radiosensitvity at all doses tested, but MSCs of both genotypes were overall significantly more IR-sensitive than WT fibroblasts (Figure 4c). As a second assay, we measured the total number of viable cells in culture, irrespective of colony-forming potential, after irradiation at doses ranging from 0 to 5 Gy. Cell suspensions of ArtΔ/Δ or WT MSCs or MEFs were irradiated, plated and cultured for 7 days, and then scored for viable cells by manual cytometry. Surviving cell counts were normalized to unirradiated cultures (Figure 4d). As in the colony formation assay, we observed the relative IR hypersensitivity in ArtΔ/Δ MEFs, but not MSCs, relative to the corresponding WT cells. Notably, by this assay, both WT and ArtΔ/Δ MSCs were more sensitive than their counterpart MEFs to IR at all doses.
Artmodulates MSC proliferation following ionizing irradiation
To measure the kinetics of mitotic response to IR, WT or ArtΔ/Δ MSCs were subjected to 1 Gy of γ-irradiation, and the mitotic index was determined by immunofluorescent detection of phosphorylated histone H3 (pH3) at 0, 6, 12 or 24 hours after irradiation (Figures 5c-g). As controls, WT or ArtΔ/Δ MEFs were similarly irradiated and analyzed, with the latter known to be hypersensitive to IR exposure. WT MSCs showed an initial increase in mitotic index following irradiation, approximately doubling by 6 hours, then declining to preirradiation levels by 12 hours (Figures 5d and 5e). Relative to WT, ArtΔ/Δ MSCs showed a prolonged mitotic response to IR, with mitotic index increasing twofold by 6 hours, reaching a peak level of 2.5-fold by 12 hours and remaining elevated at 24 hours (Figures 5d and 5e). By contrast, ArtΔ/Δ MEFs showed elevated mitotic index in unirradiated cultures relative to WT MEFs, but did not exhibit a sustained increase in mitotic index following irradiation as in WT cells (Figures 5f and 5g).
Altogether, these results suggest that Art is dispensable for overall resistance to genotoxic stress in multipotent adult MSCs, but that Art critically modulates MSC cell cycle response following ionizing irradiation. The underlying basis for the dichotomy between MSCs and fibroblasts for IR resistance is not known, but a similar phenomenon was previously observed in the context of embryonic stem cells (ESCs) [26, 41]. Art deficiency did not hypersensitize ESCs to DNA damaging agents, but WT and ArtΔ/Δ ESCs were generally more sensitive than corresponding fibroblasts. It is possible that this represents a difference in the importance of the NHEJ pathway in stem/progenitor versus more differentiated cell types.
Art-deficient MSCs are resistant to serum deprivation stress
Misregulation of stress response, proliferation and differentiation pathways in ArtΔ/ΔMSCs
GO analysis also showed that the list of 157 deregulated genes was enriched for genes annotated to the biological processes of stress response, cell proliferation and cell differentiation. Collectively, these data suggest a model in which cell stress (here via serum withdrawal) normally prompts deregulation of cell proliferation and BMP/WNT-dependent MSC differentiation pathways. We speculate that simultaneous proliferative and antiproliferative signals, evoked by cell stress, culminate in cell death, and that Art functions in part to modulate the response to these signals.
Genomic instability is recognized as a major feature of many, if not all, cancers. However, the mechanisms that maintain normal genomic integrity and their roles in preventing neoplastic transformation are not completely understood. Here we have investigated the role of the nonhomologous end joining pathway of DNA double-stranded break repair in multipotent MSCs/progenitor cells in relation to sarcomagenesis. The cancer stem cell hypothesis posits that stem or stemlike cells are responsible for cancer initiation, metastasis, therapy resistance and relapse after remission. In this context, there is growing evidence to suggest a role for MSCs or MMSs in the development of many sarcomas. Previous studies have shown that ArtΔ/Δ Trp53Δ/+ mice are susceptible to tumorigenesis with shorter latency and an altered spectrum relative to Trp53Δ/+ mice. We find overall tumor incidence in ArtΔ/Δ Trp53Δ/+ mice similar to prior studies, but observed a higher incidence of sarcomas than seen in at least one prior study . The basis for this difference in tumor spectrum is not known but may be related to differences in mouse strain background or the prolonged observation period in our study . Importantly, we find evidence for sarcomagenesis without clonal chromosomal translocation in ArtΔ/Δ cells . This is striking, given the well-documented DNA double-stranded break repair and genome stability functions of Art. Rather, we propose that defects in proliferation control following cellular stress can render Art-defective (and perhaps other NHEJ-deficient) MSCs or MMSs preneoplastic. In this context, checkpoint regulatory activities of ARTEMIS may be more important than the DSB repair function with regard to sarcoma suppression [12–14]. Taken together, our results suggest that in a sensitized genetic context or with the right series of subsequent genetic hits, potentially preneoplastic MSCs might give rise to sarcomas with differentiation into various lineages [67–69]. It will be interesting to determine, via structure-function studies, which molecular activities of ARTEMIS may differentially contribute to its lymphoma versus sarcoma suppressive functions. It will also be important to assess whether ARTEMIS is relevant to tumor suppression in other tissues, and if so, which functions are important.
In primary multipotent mesenchymal stem or stromal cells (MSC/MMS) we have shown roles for Art in both genome stability and cell proliferation control. Together these results suggest that Art may function in general DNA double-stranded break repair, as it does in other cell types. But in MSCs, Art may also integrate cell cycle responses to cellular stress. Whereas Art deficiency did not lead to overt defects in either the number or differentiation function of primary bone marrow-derived MSCs, lack of Art did result in aberrant proliferative responses to cellular stress conditions such as ionizing radiation or serum deprivation, conditions that are normally cytostatic to WT MSCs and MMSs. Our data are consistent with a growing body of evidence that ARTEMIS regulates checkpoint responses, perhaps in multiple phases of the cell cycle [11–14]. ARTEMIS is known to be a phosphorylation target of ATR and ATM kinases and was found to be important for proper recovery from both S- and G2/M checkpoints [12, 14]. Our data build on the previous studies of Art-dependent cell cycle checkpoint control in various cell types [12–14]. We now report a role for Art in cell cycle response to IR in primary MSCs. Our control data in primary fibroblasts differ somewhat from previous studies. Geng et al.  showed that wild-type human embryonic kidney (HEK)-293 cell line cultures experienced a reduced phospho-H3 staining by 6 hours after 3 Gy ionizing irradiation and began showing a rebound in phospho-H3 (and thus mitotic) cells by 12 hours after irradiation . These findings likely reflect an initial G2/M arrest in response to DNA damage, followed by recovery from arrest beginning at or before 12 hours. We found that wild-type primary MEFs experience a modest increase in phospho-H3 as early as 6 hours after 1 Gy of ionizing irradiation, and a significant increase by 12 hours. Possible explanations for the differences between our control MEF data and prior accounts may be differences in cell cycle responses in MEF versus HEK-293 cells, or could reflect kinetic differences that result from different IR doses than those described here . In either case, our overall results are consistent with previous studies, showing an important role for Art in modulating cell cycle checkpoint responses to IR. Moreover, our data may suggest a slightly different checkpoint function for Art in MSCs, where it appears to enforce, rather than overcome, the G2/M arrest, such that Art-defective MSCs remain inappropriately proliferative after IR exposure. Overall, the data presented here indicate a key cell cycle regulatory function for Art that may also be cell-context dependent [11–14, 70].
In this latter context, we find misregulation of critical growth regulatory pathways in serum-starved ArtΔ/Δ MSCs. It is not currently known whether the genes we have identified as differentially regulated in serum-starved WT versus ArtΔ/Δ MSCs directly contribute to the differences in stress sensitivity or alternatively represent biomarkers of the overall differential stress response. However, it is possible that the pathways identified by our differential gene expression analysis influence the exact checkpoint functions of ARTEMIS, perhaps in a cell type-dependent fashion, and may thus account for the phenotypic differences we observe in ArtΔ/Δ MSCs versus other cell types [12–14]. There is an accumulating literature implicating differentiation and growth factor pathways as critical in normal MSC function and homeostasis. Here we have identified BMP, WNT, and growth factor signaling pathways as differentially affected in serum-starved WT versus ArtΔ/Δ MSCs. In this context, our identification of altered BMP4 expression is intriguing in light of a recent report showing that BMP2 and BMP4 can induce cytoskeletal changes that modulate cellular differentiation via alterations of cell morphology . Another recent report has suggested that Igfbp5, which we have also identified in this study, may be a key modulator of senescence in some cellular contexts . While we cannot presently rule out other models, our findings may indicate that stress-responsive changes in MSC gene expression are linked to cell cycle control, perhaps via ARTEMIS. Given the excitement that surrounds mesenchymal stem cells and their potential in tissue bioengineering applications, it will be critical to understand the pathways that are important for their normal functioning and for preventing their neoplastic transformation. The findings presented here imply that Art encodes a critical modulator of MSC cellular stress and that the cell cycle modulatory function of Art represents a key determinant of tumorigenesis arising within tissues engineered from MSCs.
ArtΔ/Δ and Trp53Δ/+ mice were derived and maintained as previously described [8, 26, 29]. All animals were maintained in a barrier facility in accordance with Institutional Animal Care and Use Committee-approved protocols.
Multipotent stromal cell isolation and culture conditions
Total bone marrow was isolated from pools of three or four wild-type C57B6/J or Art-null mice between 6 and 10 weeks of age. Independent biological replicates were prepared from pools of independent mice from the appropriate genotypes. Total bone marrow from each pool was plated onto 1- to 150-mm tissue culture plates in 25-mL volume growth medium (α-MEM containing 10% fetal bovine serum (FBS), penicillin/streptomycin, and L-glutamate). When adherent cells became ~80% confluent (approximately day 4-6 of culture), nonadherent cells were washed away and cells were passaged onto 3- to 150-mm culture dishes and then immediately used to initiate experiments or were cryopreserved. For all experiments, only low-passage MSC preparations were used.
To prepare metaphase chromosome spreads, 40 ng/mL colcemid (KaryoMax; Invitrogen, Carlsbad, CA, USA) was added to subconfluent culturing cells to induce metaphase arrest. Cells were then transferred to hypotonic KCl solution (75 mM) for 15 min at 37°C and fixed by two changes of cold 3:1 methanol-acetic acid. Metaphase chromosome preparations were dropped onto slides and further processed for spectral karyotyping (SKY) according to the manufacturer's protocols (Applied Spectral Imaging, Corona, CA, USA). SKY imaging was performed using an ASI complete cytogenetics station (Applied Spectral Imaging) and analyzed with dedicated analysis software (Applied Spectral Imaging).
For osteocyte and adipocyte differentiation, MSCs were plated at 1 × 105 cells/35-mm well in triplicate. Twenty-four hours after plating, cultures were changed to either osteocyte-specific differentiation medium containing 10 nM dexamethasone (Sigma, St. Louis, MO, USA), 20 mM β-glycerol phosphate (Sigma), and 50 μM L-ascorbic acid (Sigma) or to adipocyte-specific differentiation medium containing 0.5 μM dexamethasone (Sigma), 0.5 μM isobutylmethylxanthine (Sigma), and 50 μM indomethacin (Sigma). Cells were treated with cell-specific differentiation medium for 7-14 days. On the final day of treatment, cells were fixed in 3% formaldehyde/2% sucrose for 10 minutes at room temperature and stained for osteocyte differentiation with alizarin red, which binds to mineralized bone or for adipocyte differentiation with LipidTOX™ (Invitrogen), which binds to neutral lipids. Two wells of each treatment were stained for the cell type generated by differentiation medium, while the third well was stained for the opposite treatment as a specificity control.
MSCs or control fibroblasts were irradiated with the indicated doses of γ-irradiation from a 137Cs source, plated in triplicate (0.5 × 105 cells/35-mm well for MSCs; 0.5 × 105 cells/60-mm plate for fibroblasts) and cultured for 7 days. Cells were then trypsinized and scraped to dissociate all adherent cells, stained with trypan blue, and counted using a hemacytometer. For immunofluorescence following irradiation, MSCs were cultured on gelatin-coated glass coverslips, irradiated at the indicated dose (ranging from 0-5 Gy), allowed to recover in culture and then fixed and processed for immunofluorescent staining (below in Immunofluorescence methods.).
Primary MSCs or MEFs were γ-irradiated at doses from 0 to 3.5 Gy with a 137Cs source. A total of 1 × 105 MEFs or 5 × 105 cells were plated onto 100-mm culture dishes and cultured until colony formation was visibly obvious for the unirradiated WT control cells. All cells were then fixed in 3% formaldehyde/2% sucrose for 10 minutes at room temperature and permeabilized with 0.5% Triton-X 100 in 1× phosphate-buffered saline (PBS) for 5 minutes at room temperature. Cells were stained in 0.5% crystal violet for 10 minutes at room temperature, and colonies were manually counted. Images were recorded by digital plate scanning.
MSCs were plated at 1 × 105 cells/35-mm well in six-well plates containing gelatinized coverslips. Cells treated with regular MSC medium were fixed in 3% formaldehyde/2% sucrose for 10 minutes at room temperature when approximately 80% confluent. Cells treated with osteocyte or adipocyte differentiation medium were fixed in the same manner on days 3, 7 and 14 of treatment. Fixed cells were permeabilized with 0.1% Triton X-100 in 1× phosphate-buffered saline for 15 minutes, blocked in 2% fetal bovine serum for 1 hour at room temperature, and stained with primary antibody to either phospho-H3 (1:200; Upstate; Millipore, Billerica, MA, USA) or phospho-H2AX (1:400; Bethyl, Montgomery, TX, USA) for 16 to 18 hours at 4°C. Cells were then incubated for 30 minutes at room temperature in FITC-labeled goat anti-rabbit IgG (Vector Laboratories, Burlingame, CA, USA) and mounted with Vectashield mounting medium containing 4',6'-diamidino-2-phenylindole counterstain (DAPI; Vector Laboratories, Burlingame, CA). Images were captured by epifluorescence wide-field imaging on a Nikon 90i upright microscope (Nikon, Melville, NY, USA). Images were analyzed using IPLab software (BD Biosciences, Rockville, MD, USA) with minimal image processing.
MSCs were plated in triplicate at a density of 0.5 × 105 cells/35-mm well. After 24 hours, cells were rinsed with PBS and transferred to standard medium with 10% FBS or to medium without serum. Cells were trypsinized, stained with trypan blue and counted on day 7 of treatment.
Gene Expression Analysis
For gene expression profiling, freshly isolated WT or ArtD/D MSCs were cultured in duplicate experiments. When cultures reached approximately 80% confluence in 15-cm culture dishes, medium was replaced with fresh basic MSC culture medium (see above in Multipotent stromal cell isolation and culturing methods) either with 10% FBS or lacking serum. Cells were incubated at 37°C in a humidified culture incubator with 5% CO2 for 24 hours. Cells were harvested by manual plate scraping, washed once in cold PBS, and stored at -20°C in RNALater (Ambion; Applied Biosciences, Austin, TX, USA) prior to RNA extraction. Standard Affymetrix protocols for Genechip Mouse 430 2.0 (Affymetrix, Santa Clara, CA, USA) were followed to isolate RNA and generate all microarray data.
List of Abbreviations
DNA double-stranded break
embryonic stem cell
Gray (= 100 rad)
mesenchymal stem cell
nonhomologous end joining
relative fold change
The authors thank Sonya Kamdar (The Jackson Laboratory) for technical assistance and support. This project was supported by grant no. 5 P20 RR018789-05 from the National Center for Research Resources (NCRR) and partly by grant no. W81XWH-07-2-0116 from the United States Department of Defense (DOD). All animal work was carried out according to Institutional Animal Care and Use Committee-approved protocols.
- Mills KD, Ferguson DO, Alt FW: The role of DNA breaks in genomic instability and tumorigenesis. Immunol Rev. 2003, 194: 77-95. 10.1034/j.1600-065X.2003.00060.x.View ArticlePubMed
- Valerie K, Povirk LF: Regulation and mechanisms of mammalian double-strand break repair. Oncogene. 2003, 22: 5792-5812. 10.1038/sj.onc.1206679.View ArticlePubMed
- Rooney S, Chaudhuri J, Alt FW: The role of the non-homologous end-joining pathway in lymphocyte development. Immunol Rev. 2004, 200: 115-131. 10.1111/j.0105-2896.2004.00165.x.View ArticlePubMed
- Zhu C, Mills KD, Ferguson DO, Lee C, Manis J, Fleming J, Gao Y, Morton CC, Alt FW: Unrepaired DNA breaks in p53-deficient cells lead to oncogenic gene amplification subsequent to translocations. Cell. 2002, 109: 811-821. 10.1016/S0092-8674(02)00770-5.View ArticlePubMed
- Moshous D, Pannetier C, Chasseval Rd R, Deist Fl F, Cavazzana-Calvo M, Romana S, Macintyre E, Canioni D, Brousse N, Fischer A, Casanova JL, Villartay JP: Partial T and B lymphocyte immunodeficiency and predisposition to lymphoma in patients with hypomorphic mutations in Artemis. J Clin Invest. 2003, 111: 381-387.PubMed CentralView ArticlePubMed
- Sharpless NE, Ferguson DO, O'Hagan RC, Castrillon DH, Lee C, Farazi PA, Alson S, Fleming J, Morton CC, Frank K, Chin L, Alt FW, DePinho RA: Impaired nonhomologous end-joining provokes soft tissue sarcomas harboring chromosomal translocations, amplifications, and deletions. Mol Cell. 2001, 8: 1187-1196. 10.1016/S1097-2765(01)00425-7.View ArticlePubMed
- Yan CT, Kaushal D, Murphy M, Zhang Y, Datta A, Chen C, Monroe B, Mostoslavsky G, Coakley K, Gao Y, Mills KD, Fazeli AP, Tepsuporn S, Hall G, Mulligan R, Fox E, Bronson R, De Girolami U, Lee C, Alt FW: XRCC4 suppresses medulloblastomas with recurrent translocations in p53-deficient mice. Proc Natl Acad Sci USA. 2006, 103: 7378-7383. 10.1073/pnas.0601938103.PubMed CentralView ArticlePubMed
- Woo Y, Wright SM, Maas SA, Alley TL, Caddle LB, Kamdar S, Affourtit J, Foreman O, Akeson EC, Shaffer D, Bronson RT, Morse HC, Roopenian D, Mills KD: The nonhomologous end joining factor Artemis suppresses multi-tissue tumor formation and prevents loss of heterozygosity. Oncogene. 2007, 26: 6010-6020. 10.1038/sj.onc.1210430.View ArticlePubMed
- Jeggo P, O'Neill P: The Greek Goddess, Artemis, reveals the secrets of her cleavage. DNA Repair (Amsterdam). 2002, 1: 771-777. 10.1016/S1568-7864(02)00096-4.View Article
- Moshous D, Callebaut I, de Chasseval R, Corneo B, Cavazzana-Calvo M, Le Deist F, Tezcan I, Sanal O, Bertrand Y, Philippe N, Fischer A, de Villartay JP: Artemis, a Novel DNA double-strand break repair/V(D)J recombination protein, is mutated in human severe combined immune deficiency. Cell. 2001, 105: 177-186. 10.1016/S0092-8674(01)00309-9.View ArticlePubMed
- Zhang X, Zhu Y, Geng L, Wang H, Legerski RJ: Artemis is a negative regulator of p53 in response to oxidative stress. Oncogene. 2009, 28: 2196-2204. 10.1038/onc.2009.100.PubMed CentralView ArticlePubMed
- Wang H, Zhang X, Geng L, Teng L, Legerski RJ: Artemis regulates cell cycle recovery from the S phase checkpoint by promoting degradation of cyclin E. J Biol Chem. 2009, 284: 18236-18243. 10.1074/jbc.M109.002584.PubMed CentralView ArticlePubMed
- Geng L, Zhang X, Zheng S, Legerski RJ: Artemis links ATM to G2/M checkpoint recovery via regulation of Cdk1-cyclin B. Mol Cell Biol. 2007, 27: 2625-2635. 10.1128/MCB.02072-06.PubMed CentralView ArticlePubMed
- Zhang X, Succi J, Feng Z, Prithivirajsingh S, Story MD, Legerski RJ: Artemis is a phosphorylation target of ATM and ATR and is involved in the G2/M DNA damage checkpoint response. Mol Cell Biol. 2004, 24: 9207-9220. 10.1128/MCB.24.20.9207-9220.2004.PubMed CentralView ArticlePubMed
- Richie CT, Peterson C, Lu T, Hittelman WN, Carpenter PB, Legerski RJ: hSnm1 colocalizes and physically associates with 53BP1 before and after DNA damage. Mol Cell Biol. 2002, 22: 8635-8647. 10.1128/MCB.22.24.8635-8647.2002.PubMed CentralView ArticlePubMed
- Li L, Moshous D, Zhou Y, Wang J, Xie G, Salido E, Hu D, de Villartay JP, Cowan MJ: A founder mutation in Artemis, an SNM1-like protein, causes SCID in Athabascan-speaking Native Americans. J Immunol. 2002, 168: 6323-6329.View ArticlePubMed
- Noordzij JG, Verkaik NS, van der Burg M, van Veelen LR, de Bruin-Versteeg S, Wiegant W, Vossen JM, Weemaes CM, de Groot R, Zdzienicka MZ, van Gent DC, van Dongen JJ: Radiosensitive SCID patients with Artemis gene mutations show a complete B-cell differentiation arrest at the pre-B-cell R checkpoint in bone marrow. Blood. 2003, 101: 1446-1452. 10.1182/blood-2002-01-0187.View ArticlePubMed
- Villa A, Sobacchi C, Vezzoni P: Omenn syndrome in the context of other B cell-negative severe combined immunodeficiencies. Isr Med Assoc J. 2002, 4: 218-221.PubMed
- Reger RL, Tucker AH, Wolfe MR: Differentiation and characterization of human MSCs. Methods Mol Biol. 2008, 449: 93-107. full_text.PubMed
- Phinney DG, Prockop DJ: Concise review: mesenchymal stem/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair: current views. Stem Cells. 2007, 25: 2896-2902. 10.1634/stemcells.2007-0637.View ArticlePubMed
- Dennis JE, Charbord P: Origin and differentiation of human and murine stroma. Stem Cells. 2002, 20: 205-214. 10.1634/stemcells.20-3-205.View ArticlePubMed
- Minguell JJ, Erices A, Conget P: Mesenchymal stem cells. Exp Biol Med (Maywood). 2001, 226: 507-520.
- Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR: Multilineage potential of adult human mesenchymal stem cells. Science. 1999, 284: 143-147. 10.1126/science.284.5411.143.View ArticlePubMed
- Barrilleaux B, Phinney DG, Prockop DJ, O'Connor KC: Review: ex vivo engineering of living tissues with adult stem cells. Tissue Eng. 2006, 12: 3007-3019. 10.1089/ten.2006.12.3007.View ArticlePubMed
- Gregory CA, Prockop DJ, Spees JL: Non-hematopoietic bone marrow stem cells: molecular control of expansion and differentiation. Exp Cell Res. 2005, 306: 330-335. 10.1016/j.yexcr.2005.03.018.View ArticlePubMed
- Rooney S, Sekiguchi J, Zhu C, Cheng HL, Manis J, Whitlow S, DeVido J, Foy D, Chaudhuri J, Lombard D, Alt FW: Leaky SCID phenotype associated with defective V(D)J coding end processing in Artemis-deficient mice. Mol Cell. 2002, 10: 1379-1390. 10.1016/S1097-2765(02)00755-4.View ArticlePubMed
- Jacks T, Remington L, Williams BO, Schmitt EM, Halachmi S, Bronson RT, Weinberg RA: Tumor spectrum analysis in p53-mutant mice. Curr Biol. 1994, 4: 1-7. 10.1016/S0960-9822(00)00002-6.View ArticlePubMed
- Harvey M, McArthur MJ, Montgomery CA, Butel JS, Bradley A, Donehower LA: Spontaneous and carcinogen-induced tumorigenesis in p53-deficient mice. Nat Genet. 1993, 5: 225-229. 10.1038/ng1193-225.View ArticlePubMed
- Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA, Butel JS, Bradley A: Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature. 1992, 356: 215-221. 10.1038/356215a0.View ArticlePubMed
- Rooney S, Sekiguchi J, Whitlow S, Eckersdorff M, Manis JP, Lee C, Ferguson DO, Alt FW: Artemis and p53 cooperate to suppress oncogenic N-myc amplification in progenitor B cells. Proc Natl Acad Sci USA. 2004, 101: 2410-2415. 10.1073/pnas.0308757101.PubMed CentralView ArticlePubMed
- Meng GZ, Zhang HY, Zhang Z, Wei B, Bu H: Myofibroblastic sarcoma vs nodular fasciitis: a comparative study of chromosomal imbalances. Am J Clin Pathol. 2009, 131: 701-709. 10.1309/AJCPV6H2WSYXLKFB.View ArticlePubMed
- Isaka T, Nestor AL, Takada T, Allison DC: Chromosomal variations within aneuploid cancer lines. J Histochem Cytochem. 2003, 51: 1343-1353.View ArticlePubMed
- Lauwers GY, Grant LD, Donnelly WH, Meloni AM, Foss RM, Sanberg AA, Langham MR: Hepatic undifferentiated (embryonal) sarcoma arising in a mesenchymal hamartoma. Am J Surg Pathol. 1997, 21: 1248-1254. 10.1097/00000478-199710000-00018.View ArticlePubMed
- Hoogerwerf WA, Hawkins AL, Perlman EJ, Griffin CA: Chromosome analysis of nine osteosarcomas. Genes Chromosomes Cancer. 1994, 9: 88-92. 10.1002/gcc.2870090203.View ArticlePubMed
- Travis JA, Bridge JA: Significance of both numerical and structural chromosomal abnormalities in clear cell sarcoma. Cancer Genet Cytogenet. 1992, 64: 104-106. 10.1016/0165-4608(92)90337-8.View ArticlePubMed
- Vanden Berg E, Molenaar WM, Hoekstra HJ, Kamps WA, de Jong B: DNA ploidy and karyotype in recurrent and metastatic soft tissue sarcomas. Mod Pathol. 1992, 5: 505-514.
- Sreekantaiah C, Leong SP, Davis JR, Sandberg AA: Cytogenetic and flow cytometric analysis of a clear cell chondrosarcoma. Cancer Genet Cytogenet. 1991, 52: 193-199. 10.1016/0165-4608(91)90463-5.View ArticlePubMed
- Hiddemann W, Roessner A, Wormann B, Mellin W, Klockenkemper B, Bosing T, Buchner T, Grundmann E: Tumor heterogeneity in osteosarcoma as identified by flow cytometry. Cancer. 1987, 59: 324-328. 10.1002/1097-0142(19870115)59:2<324::AID-CNCR2820590226>3.0.CO;2-9.View ArticlePubMed
- Potluri VR, Gilbert F: A cytogenetic study of embryonal rhabdomyosarcoma. Cancer Genet Cytogenet. 1985, 14: 169-173. 10.1016/0165-4608(85)90228-6.View ArticlePubMed
- Smith A, Roberts C, van Haaften-Day C, den Dulk G, Russell P, Tattersall MH: Cytogenetic findings in cell lines derived from four ovarian carcinomas. Cancer Genet Cytogenet. 1987, 24: 231-242. 10.1016/0165-4608(87)90104-X.View ArticlePubMed
- Gilbert F: Solid tumors of children: chromosome abnormalities and the development of cancer. J Cell Physiol Suppl. 1984, 3: 165-170. 10.1002/jcp.1041210419.View ArticlePubMed
- Rooney S, Alt FW, Lombard D, Whitlow S, Eckersdorff M, Fleming J, Fugmann S, Ferguson DO, Schatz DG, Sekiguchi J: Defective DNA repair and increased genomic instability in Artemis-deficient murine cells. J Exp Med. 2003, 197: 553-565. 10.1084/jem.20021891.PubMed CentralView ArticlePubMed
- Reger RL, Wolfe MR: Freezing harvested hMSCs and recovery of hMSCs from frozen vials for subsequent expansion, analysis, and experimentation. Methods Mol Biol. 2008, 449: 109-116. full_text.PubMed
- Potier E, Ferreira E, Meunier A, Sedel L, Logeart-Avramoglou D, Petite H: Prolonged hypoxia concomitant with serum deprivation induces massive human mesenchymal stem cell death. Tissue Eng. 2007, 13: 1325-1331. 10.1089/ten.2006.0325.View ArticlePubMed
- Zhu W, Chen J, Cong X, Hu S, Chen X: Hypoxia and serum deprivation-induced apoptosis in mesenchymal stem cells. Stem Cells. 2006, 24: 416-425. 10.1634/stemcells.2005-0121.View ArticlePubMed
- Cleton-Jansen AM, Anninga JK, Briaire-de Bruijn IH, Romeo S, Oosting J, Egeler RM, Gelderblom H, Taminiau AH, Hogendoorn PC: Profiling of high-grade central osteosarcoma and its putative progenitor cells identifies tumourigenic pathways. Br J Cancer. 2009, 101: 1909-1918. 10.1038/sj.bjc.6605405.PubMed CentralView ArticlePubMed
- Courtwright A, Siamakpour-Reihani S, Arbiser JL, Banet N, Hilliard E, Fried L, Livasy C, Ketelsen D, Nepal DB, Perou CM, Patterson C, Klauber-Demore N: Secreted frizzle-related protein 2 stimulates angiogenesis via a calcineurin/NFAT signaling pathway. Cancer Res. 2009, 69: 4621-4628. 10.1158/0008-5472.CAN-08-3402.PubMed CentralView ArticlePubMed
- Enomoto M, Hayakawa S, Itsukushima S, Ren DY, Matsuo M, Tamada K, Oneyama C, Okada M, Takumi T, Nishita M, Minami Y: Autonomous regulation of osteosarcoma cell invasiveness by Wnt5a/Ror2 signaling. Oncogene. 2009, 28: 3197-3208. 10.1038/onc.2009.175.View ArticlePubMed
- Hou CH, Hsiao YC, Fong YC, Tang CH: Bone morphogenetic protein-2 enhances the motility of chondrosarcoma cells via activation of matrix metalloproteinase-13. Bone. 2009, 44: 233-242. 10.1016/j.bone.2008.09.021.View ArticlePubMed
- Kansara M, Tsang M, Kodjabachian L, Sims NA, Trivett MK, Ehrich M, Dobrovic A, Slavin J, Choong PF, Simmons PJ, Dawid IB, Thomas DM: Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice. J Clin Invest. 2009, 119: 837-851. 10.1172/JCI37175.PubMed CentralView ArticlePubMed
- Karim RZ, Gerega SK, Yang YH, Horvath L, Spillane A, Carmalt H, Scolyer RA, Lee CS: Proteins from the Wnt pathway are involved in the pathogenesis and progression of mammary phyllodes tumours. J Clin Pathol. 2009, 62: 1016-1020. 10.1136/jcp.2009.066977.View ArticlePubMed
- Kurihara S, Oda Y, Ohishi Y, Kaneki E, Kobayashi H, Wake N, Tsuneyoshi M: Coincident expression of beta-catenin and cyclin D1 in endometrial stromal tumors and related high-grade sarcomas. Mod Pathol. 2009, 23: 225-34. 10.1038/modpathol.2009.162.View ArticlePubMed
- Chen K, Fallen S, Abaan HO, Hayran M, Gonzalez C, Wodajo F, MacDonald T, Toretsky JA, Uren A: Wnt10b induces chemotaxis of osteosarcoma and correlates with reduced survival. Pediatr Blood Cancer. 2008, 51: 349-355. 10.1002/pbc.21595.View ArticlePubMed
- Fong YC, Li TM, Wu CM, Hsu SF, Kao ST, Chen RJ, Lin CC, Liu SC, Wu CL, Tang CH: BMP-2 increases migration of human chondrosarcoma cells via PI3K/Akt pathway. J Cell Physiol. 2008, 217: 846-855. 10.1002/jcp.21568.View ArticlePubMed
- Guo Y, Xie J, Rubin E, Tang YX, Lin F, Zi X, Hoang BH: Frzb, a secreted Wnt antagonist, decreases growth and invasiveness of fibrosarcoma cells associated with inhibition of Met signaling. Cancer Res. 2008, 68: 3350-3360. 10.1158/0008-5472.CAN-07-3220.PubMed CentralView ArticlePubMed
- Luo X, Chen J, Song WX, Tang N, Luo J, Deng ZL, Sharff KA, He G, Bi Y, He BC, Bennett E, Huang J, Kang Q, Jiang W, Su Y, Zhu GH, Yin H, He Y, Wang Y, Souris JS, Chen L, Zuo GW, Montag AG, Reid RR, Haydon RC, Luu HH, He TC: Osteogenic BMPs promote tumor growth of human osteosarcomas that harbor differentiation defects. Lab Invest. 2008, 88: 1264-1277. 10.1038/labinvest.2008.98.View ArticlePubMed
- Matushansky I, Maki RG, Cordon-Cardo C: A context dependent role for Wnt signaling in tumorigenesis and stem cells. Cell Cycle. 2008, 7: 720-724. 10.4161/cc.7.6.5569.View ArticlePubMed
- Bhat RA, Stauffer B, Komm BS, Bodine PV: Structure-function analysis of secreted frizzled-related protein-1 for its Wnt antagonist function. J Cell Biochem. 2007, 102: 1519-1528. 10.1002/jcb.21372.View ArticlePubMed
- Dong YF, Soung do Y, Schwarz EM, O'Keefe RJ, Drissi H: Wnt induction of chondrocyte hypertrophy through the Runx2 transcription factor. J Cell Physiol. 2006, 208: 77-86. 10.1002/jcp.20656.View ArticlePubMed
- Sotobori T, Ueda T, Myoui A, Yoshioka K, Nakasaki M, Yoshikawa H, Itoh K: Bone morphogenetic protein-2 promotes the haptotactic migration of murine osteoblastic and osteosarcoma cells by enhancing incorporation of integrin beta1 into lipid rafts. Exp Cell Res. 2006, 312: 3927-3938. 10.1016/j.yexcr.2006.08.024.View ArticlePubMed
- Weiss KR, Cooper GM, Jadlowiec JA, McGough RL, Huard J: VEGF and BMP expression in mouse osteosarcoma cells. Clin Orthop Relat Res. 2006, 450: 111-117. 10.1097/01.blo.0000229333.98781.56.View ArticlePubMed
- Baird K, Davis S, Antonescu CR, Harper UL, Walker RL, Chen Y, Glatfelter AA, Duray PH, Meltzer PS: Gene expression profiling of human sarcomas: insights into sarcoma biology. Cancer Res. 2005, 65: 9226-9235. 10.1158/0008-5472.CAN-05-1699.View ArticlePubMed
- Chandar N, Swindle J, Szajkovics A, Kolman K: Relationship of bone morphogenetic protein expression during osteoblast differentiation to wild type p53. J Orthop Res. 2005, 23: 1345-1353.View ArticlePubMed
- Yoshikawa H, Nakase T, Myoui A, Ueda T: Bone morphogenetic proteins in bone tumors. J Orthop Sci. 2004, 9: 334-340. 10.1007/s00776-004-0764-9.View ArticlePubMed
- Gobbi G, Sangiorgi L, Lenzi L, Casadei R, Canaider S, Strippoli P, Lucarelli E, Ghedini I, Donati D, Fabbri N, Warzecha J, Yeoung C, Helman LJ, Picci P, Carinci P: Seven BMPs and all their receptors are simultaneously expressed in osteosarcoma cells. Int J Oncol. 2002, 20: 143-147.PubMed
- Sulzbacher I, Birner P, Trieb K, Pichlbauer E, Lang S: The expression of bone morphogenetic proteins in osteosarcoma and its relevance as a prognostic parameter. J Clin Pathol. 2002, 55: 381-385.PubMed CentralView ArticlePubMed
- Miura M, Miura Y, Padilla-Nash HM, Molinolo AA, Fu B, Patel V, Seo BM, Sonoyama W, Zheng JJ, Baker CC, Chen W, Ried T, Shi S: Accumulated chromosomal instability in murine bone marrow mesenchymal stem cells leads to malignant transformation. Stem Cells. 2006, 24: 1095-1103. 10.1634/stemcells.2005-0403.View ArticlePubMed
- Tolar J, Nauta AJ, Osborn MJ, Panoskaltsis Mortari A, McElmurry RT, Bell S, Xia L, Zhou N, Riddle M, Schroeder TM, Westendorf JJ, McIvor RS, Hogendoorn PC, Szuhai K, Oseth L, Hirsch B, Yant SR, Kay MA, Peister A, Prockop DJ, Fibbe WE, Blazar BR: Sarcoma derived from cultured mesenchymal stem cells. Stem Cells. 2007, 25: 371-379. 10.1634/stemcells.2005-0620.View ArticlePubMed
- Charytonowicz E, Cordon-Cardo C, Matushansky I, Ziman M: Alveolar rhabdomyosarcoma: is the cell of origin a mesenchymal stem cell?. Cancer Lett. 2009, 279: 126-136. 10.1016/j.canlet.2008.09.039.View ArticlePubMed
- Jeggo PA, Lobrich M: Artemis links ATM to double strand break rejoining. Cell Cycle. 2005, 4: 359-362.View ArticlePubMed
- Huang HY, Hu LL, Song TJ, Li X, He Q, Sun X, Li YM, Lu HJ, Yang PY, Tang QQ: Involvement of cytoskeleton-associated proteins in the commitment of C3H10T1/2 pluripotent stem cells to adipocyte lineage induced by BMP2/4. Mol Cell Proteomics. 2010
- Allan GJ, Beattie J, Flint DJ: Epithelial injury induces an innate repair mechanism linked to cellular senescence and fibrosis involving IGF-binding protein-5. J Endocrinol. 2008, 199: 155-164. 10.1677/JOE-08-0269.View ArticlePubMed
- Anderson HC, Reynolds PR, Hsu HH, Missana L, Masuhara K, Moylan PE, Roach HI: Selective synthesis of bone morphogenetic proteins-1, -3, -4 and bone sialoprotein may be important for osteoinduction by Saos-2 cells. J Bone Miner Metab. 2002, 20: 73-82. 10.1007/s007740200010.View ArticlePubMed
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.